Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Sarcoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Rhabdoid Tumor 3Lymphoma, B-Cell 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Cyclophosphamide 30Rituximab 26Biopsy 23Specimen Handling 20Magnetic Resonance Spectroscopy 18fludarabine 14Prednisone 13Vincristine 11obinutuzumab 10Lenalidomide 10Etoposide 10Doxorubicin 10Bendamustine Hydrochloride 9pembrolizumab 7venetoclax 6fludarabine phosphate 6X-Rays 6Tacrolimus 6Nuclear Medicine Department, Hospital 6Dexamethasone 6Bortezomib 6trametinib 5ibrutinib 5glofitamab 5acalabrutinib 5Mycophenolic Acid 5Gemcitabine 5Crizotinib 5Busulfan 5copanlisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × tazemetostat × 90 days × Clear all
NCT05983965 2026-04-17

Study of Tazemetostat in Lymphoid Malignancies

University of Alabama at Birmingham

Phase 1 Terminated
6 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, T-Cell

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡